Deutsche Bank
AVIR icon

Deutsche Bank’s Atea Pharmaceuticals AVIR Stock Holding History

Deutsche Bank’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$327K Buy
70,400
+4,714
+7% +$23.4K ﹤0.01% 2996
2026
Q1 		$353K Buy
65,686
+12,972
+25% +$59.6K ﹤0.01% 2752
2025
Q4 		$188K Buy
+52,714
New +$168K ﹤0.01% 3041
2025
Q3 		– Sell
-42,967
Closed -$155K – 3608
2025
Q2 		$155K Sell
42,967
-17,296
-29% -$51.6K ﹤0.01% 3076
2025
Q1 		$180K Buy
+60,263
New +$188K ﹤0.01% 3002
2024
Q4 		– Sell
-49,567
Closed -$166K – 3608
2024
Q3 		$166K Buy
49,567
+17,118
+53% +$62.1K ﹤0.01% 3008
2024
Q2 		$107K Sell
32,449
-7,941
-20% -$29.6K ﹤0.01% 3087
2024
Q1 		$163K Buy
40,390
+1,915
+5% +$7.5K ﹤0.01% 2942
2023
Q4 		$117K Sell
38,475
-1,847
-5% -$5.59K ﹤0.01% 3148
2023
Q3 		$121K Buy
40,322
+3,003
+8% +$10.2K ﹤0.01% 3065
2023
Q2 		$140K Sell
37,319
-19,887
-35% -$74.5K ﹤0.01% 3089
2023
Q1 		$192K Buy
57,206
+25,722
+82% +$104K ﹤0.01% 3028
2022
Q4 		$151K Buy
31,484
+510
+2% +$2.58K ﹤0.01% 3110
2022
Q3 		$176K Sell
30,974
-235,604
-88% -$1.8M ﹤0.01% 3014
2022
Q2 		$1.89M Buy
266,578
+19,784
+8% +$135K ﹤0.01% 1795
2022
Q1 		$1.78M Buy
246,794
+173,579
+237% +$1.18M ﹤0.01% 1972
2021
Q4 		$654K Sell
73,215
-20,692
-22% -$322K ﹤0.01% 2673
2021
Q3 		$3.29M Buy
93,907
+55,150
+142% +$1.53M ﹤0.01% 1749
2021
Q2 		$833K Buy
38,757
+29,048
+299% +$873K ﹤0.01% 2885
2021
Q1 		$600K Sell
9,709
-885
-8% -$59.8K ﹤0.01% 2985
2020
Q4 		$443K Buy
+10,594
New +$341K ﹤0.01% 2988

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Deutsche Bank's AVIR Position: Q2 2026 in Review

Deutsche Bank increased its Atea Pharmaceuticals (AVIR) stake by 7.2% in Q2 2026, buying an estimated $23.4K and bringing the position to 70,400 shares worth $327K. The position accounts for ﹤0.01% of the portfolio, ranked #2996.

Deutsche Bank first reported a position in AVIR in Q4 2020 and has held it in 21 quarters since. The position peaked at $3.29M in Q3 2021. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Deutsche Bank held 70,400 shares of Atea Pharmaceuticals worth $327K as of Q2 2026.
  • Deutsche Bank bought 4,714 Atea Pharmaceuticals shares in Q2 2026, an estimated $23.4K.
  • Atea Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #2996 holding.
  • Deutsche Bank first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • Deutsche Bank's Atea Pharmaceuticals position peaked at $3.29M in Q3 2021.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.